Portfolio company
ANERGIS SA
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Anergis SA develops ultra-fast synthetic vaccines to treat patients suffering from frequent environmental allergies such as birch pollen and house dust mites.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Desentum
This biopharmaceutical company develops allergen immunotherapy products to treat patients suffering from respiratory and food allergies.
Allergios
This company develops a cell-based diagnostic platform for clinicians to perform precise in vitro allergy tests using blood samples and automated visual analysis.
Tolergyx
This company develops gastrointestinal immunotherapy capsules to treat food allergies in pediatric and adult patients.
Resistentia Pharmaceuticals AB
This company develops immunotherapeutic products for patients suffering from allergic asthma and inflammatory disorders.
ARS Pharmaceuticals
ARS Pharmaceuticals develops a needle-free nasal spray for patients and caregivers to treat severe allergic reactions, including anaphylaxis.
Pharmexa A/S
This company develops active immunotherapy and peptide vaccines for patients with cancer, chronic illnesses, and infectious diseases.
Apitope
Apitope develops antigen-specific peptide therapeutics to treat autoimmune diseases and allergies for patients requiring targeted immunotherapy and immune tolerance restoration.
Alladapt Immunotherapeutics
This biopharmaceutical company develops oral immunotherapies for patients with single or multiple food allergies to reduce the severity of allergic reactions.
